NASDAQ$RIGL
Rigel Pharmaceuticals Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Rigel Pharmaceuticals Inc reported strong Q2 2025 financial results driven by robust product sales growth and a significant collaboration revenue recognition.
Rigel achieved total revenues of $101.7 million in the second quarter of 2025, including $58.9 million in net product sales from TAVALISSE, REZLIDHIA and GAVRETO. The company recorded net income of $59.6 million or $3.33 per basic share, a substantial improvement from the prior year loss, aided by a $40 million non-cash revenue release from the Lilly collaboration.
- Total revenues reached $101.7 million, more than doubling year-over-year with product sales contributing $58.9 million.
- Net income of $59.6 million reflected strong operational leverage and the release of a $40 million cost share liability from Lilly.
- R&D expenses were $6.8 million while SG&A expenses totaled $29.3 million as the company supported commercial activities.
- Cash and short-term investments stood at $108.4 million at quarter end, providing a solid liquidity position.
Headline financials
Revenue & EPS history
Rigel · Revenue · Quarterly
$102M
Revenue by segment
Rigel · $102M total across 2 segments · Q2 2025
- Product sales, net$58.9M—58.0%
- Contract revenues from collaborations$42.7M—42.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+0.2%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+2.8%
Avg return
30 days after
38%
25 / 65 earnings
Positive
+46.4%
Q3 2024
Best reaction
-18.7%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -4.8% | -11.8% | +2.3% | |
| Q4 2025 | -10.2% | -15.0% | -16.6% | |
| Q3 2025 | -2.6% | +10.6% | +35.4% | |
| Q1 2025 | +0.9% | +1.9% | +17.7% | |
| Q4 2024 | -8.1% | -11.5% | -21.9% | |
| Q3 2024 | +46.4% | +80.5% | +68.8% | |
| Q2 2024 | +12.2% | +16.0% | +52.4% | |
| Q1 2024 | -18.7% | -19.7% | -21.3% | |
| Q4 2023 | +6.1% | +6.8% | -12.2% | |
| Q3 2023 | +5.8% | -2.4% | +35.7% | |
| Q2 2023 | -6.5% | -11.6% | -17.4% | |
| Q1 2023 | -3.4% | -0.8% | +17.6% | |
| Q4 2022 | +17.8% | +4.6% | -17.8% | |
| Q3 2022 | +5.3% | +4.3% | +18.6% | |
| Q2 2022 | +16.5% | +25.6% | +27.3% | |
| Q1 2022 | +7.3% | -9.8% | -32.5% | |
| Q4 2021 | +21.1% | +21.1% | +19.1% | |
| Q3 2021 | -1.7% | -8.8% | -26.3% | |
| Q2 2021 | -7.2% | -5.2% | +3.2% | |
| Q1 2021 | -5.2% | -7.8% | +15.7% | |
| Q4 2020 | -14.3% | -14.1% | -23.3% | |
| Q3 2020 | -3.0% | +1.5% | +14.1% | |
| Q2 2020 | +3.7% | +6.2% | -4.5% | |
| Q1 2020 | -2.2% | -2.7% | +2.2% | |
| Q4 2019 | -2.3% | +0.5% | -27.6% | |
| Q3 2019 | -1.9% | +4.7% | -5.1% | |
| Q2 2019 | +8.1% | +1.9% | -15.7% | |
| Q1 2019 | -5.5% | -6.7% | -14.7% | |
| Q4 2018 | -0.9% | -1.8% | +13.7% | |
| Q3 2018 | +7.2% | -2.7% | -3.8% | |
| Q2 2018 | +10.2% | +1.1% | +16.8% | |
| Q1 2018 | +5.3% | +7.2% | -10.0% | |
| Q4 2017 | +13.5% | +14.5% | -18.1% | |
| Q3 2017 | +1.1% | +1.6% | +2.4% | |
| Q2 2017 | -1.3% | +1.7% | +7.6% | |
| Q1 2017 | -9.9% | -9.2% | -19.1% | |
| Q4 2016 | +2.6% | +0.8% | +14.3% | |
| Q3 2016 | -3.1% | +1.5% | -3.5% | |
| Q2 2016 | +14.3% | +22.7% | +37.5% | |
| Q1 2016 | -10.9% | — | — | |
| Q4 2015 | -6.3% | — | — | |
| Q3 2015 | +8.9% | — | — | |
| Q2 2015 | +4.6% | — | — | |
| Q1 2015 | -10.5% | — | — | |
| Q4 2014 | -1.0% | — | — | |
| Q3 2014 | -1.5% | — | — | |
| Q2 2014 | -6.2% | — | — | |
| Q1 2014 | -10.6% | — | — | |
| Q4 2013 | +17.5% | — | — | |
| Q3 2013 | -9.3% | — | — | |
| Q2 2013 | +2.8% | — | — | |
| Q1 2013 | -0.6% | — | — | |
| Q4 2012 | +5.5% | — | — | |
| Q3 2012 | +2.7% | — | — | |
| Q2 2012 | -7.1% | — | — | |
| Q1 2012 | -2.1% | — | — | |
| Q4 2009 | -9.0% | — | — | |
| Q4 2011 | -9.0% | — | — | |
| Q3 2010 | -5.9% | — | — | |
| Q3 2011 | -5.9% | — | — | |
| Q2 2010 | -3.3% | — | — | |
| Q4 2010 | -3.3% | — | — | |
| Q2 2011 | -3.3% | — | — | |
| Q1 2011 | -11.5% | — | — | |
| Q1 2010 | -5.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro